Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Revenue projections:

Revenue projections for TMO
Revenue projections for TMO

Investors may react cautiously to news that Thermo Fisher Scientific Inc.'s revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 1.890000
forwardPE 17.054157
debtToEquity 77.255000
earningsGrowth 0.093000
revenueGrowth 0.072000
grossMargins 0.410760
operatingMargins 0.211710
trailingEps 17.730000
forwardEps 27.365760

With a current ratio 1.89, Thermo Fisher Scientific Inc. demonstrates the ability to service its short-term debt without difficulty. The company's strong cash reserves and current assets ensure that it can meet its liabilities, reflecting financial stability and healthy liquidity.
TMO's Forward PE is in a favorable range, meaning its stock price compares well with its earnings and isn't overpriced. This leaves room for growth, making it a compelling opportunity for investors looking to benefit from potential future gains.
Positive gross and operating margins for Thermo Fisher Scientific Inc. demonstrate the company's profitability. These margins reflect strong financial performance, with efficient operations contributing to the company's ability to generate consistent profits.
With TMO's forward EPS higher than its trailing EPS, the company is expected to be more profitable in the current financial year. This signals confidence in TMO's growth potential, as improved earnings are forecasted compared to the prior year's performance.

Price projections:

Price projections for TMO
Price projections for TMO

Over time, price projections for TMO have gradually risen, signaling growing optimism about the company's future. This upward revision reflects increasing confidence in TMO's ability to achieve strong financial results.

Insider Transactions:

Insider Transactions for TMO
Insider Transactions for TMO


27 sell transactions of TMO were recorded, with market price hovering near 528.4326533564815.There were no sell transactions recorded during the period under consideration.TMO is seeing more buys than sells at current price levels, which may indicate a positive market outlook. This trend suggests growing confidence among investors, who appear to expect favorable performance from the stock.

Recommendation changes over time:

Recommendations trend for TMO
Recommendations trend for TMO


The analysts' recent buy bias for TMO indicates strong confidence in the stock's future performance. This could encourage more investors to view TMO as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.